Skip to main content
    E

    Edwards Lifesciences Corp (EW)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $107.11
    -0.04 (-0.04%)

    Market Cap: $61.61B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Edwards Lifesciences Corp (EW) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Edwards Lifesciences (EW) is expected to report earnings on Feb 8, 2027. In the quarter ended Sep 30, 2026, Edwards Lifesciences reported EPS of $0.80, above the $0.73 estimate. It beat the EPS estimate in 7 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    75%(30/40)
    Avg Surprise
    +7.72%
    Streak
    3 Q

    Upcoming Estimates

    Reports Feb 8, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.69
    Range$0.63 - $0.79
    28 analysts
    Revenue Consensus
    $1.76B
    Range$1.66B - $1.88B
    29 analysts
    Reports Apr 21, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.84
    Range$0.77 - $0.90
    19 analysts
    EPS Revisions
    3
    5
    30d
    EPS Estimate DriftChange to current
    90d ago$0.83+1.2%
    60d ago$0.83+1.2%
    30d ago$0.83+1.2%
    7d ago$0.83+1.3%
    Current$0.84
    Revenue Consensus
    $1.80B
    Range$1.77B - $1.84B
    18 analysts

    Next Report

    EW has an expected report date of Feb 8, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 19.0% above the $0.58 reported for the quarter ended Dec 31, 2025.

    EW Earnings Call

    The latest EW earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, EW beat 30, missed 7 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $1.72B, up 11.0% from $1.55B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.80$0.73$0.72 - $0.77+9.59%Beat+19.4%240 up, 1 downNov 4, 2026$1.72B
    Jun 30, 2026$0.78$0.73$0.73 - $0.76+6.85%Beat+16.4%221 up, 1 downJul 23, 2026$1.74B
    Mar 31, 2026$0.78$0.73$0.71 - $0.75+6.85%Beat+21.9%2413 up, 2 downApr 23, 2026$1.65B
    Dec 31, 2025$0.58$0.62$0.60 - $0.65-6.39%Miss-1.7%276 up, 2 downFeb 10, 2026$1.57B
    Sep 30, 2025$0.67$0.59$0.57 - $0.62+13.56%Beat0.0%256 up, 1 downOct 30, 2025$1.55B
    Jun 30, 2025$0.67$0.62$0.60 - $0.65+8.06%Beat-4.3%261 up, 0 downJul 24, 2025$1.53B
    Mar 31, 2025$0.64$0.60$0.57 - $0.64+6.67%Beat-3.0%260 up, 1 downApr 23, 2025$1.41B
    Dec 31, 2024$0.59$0.55$0.53 - $0.64+6.38%Beat-7.8%271 up, 1 downFeb 11, 2025$1.39B
    Sep 30, 2024$0.67$0.59$0.54 - $0.70+13.56%Beat+13.6%261 up, 1 downOct 24, 2024$1.35B
    Jun 30, 2024$0.70$0.69$0.67 - $0.71+1.45%Beat+6.1%262 up, 1 downJul 24, 2024$1.37B
    Mar 31, 2024$0.66$0.64$0.63 - $0.66+3.13%Beat+6.5%250 up, 1 downApr 25, 2024$1.33B
    Dec 31, 2023$0.64$0.64$0.62 - $0.670.00%In line0.0%251 up, 0 downFeb 6, 2024$1.01B
    Sep 30, 2023$0.59$0.59$0.57 - $0.610.00%In line-3.3%250 up, 0 downOct 25, 2023$1.24B
    Jun 30, 2023$0.66$0.65$0.62 - $0.66+1.54%Beat+4.8%231 up, 0 downJul 26, 2023$1.30B
    Mar 31, 2023$0.62$0.61$0.55 - $0.64+1.64%Beat+3.3%220 up, 0 downApr 26, 2023$1.46B
    Dec 31, 2022$0.64$0.61$0.57 - $0.63+4.92%Beat+25.5%220 up, 1 downJan 31, 2023$429.90M
    Sep 30, 2022$0.61$0.62$0.61 - $0.65-1.61%Miss+13.0%230 up, 1 downOct 27, 2022$1.32B
    Jun 30, 2022$0.63$0.64$0.62 - $0.66-1.56%Miss-1.6%201 up, 1 downJul 28, 2022$1.37B
    Mar 31, 2022$0.60$0.57$0.55 - $0.60+5.26%Beat+11.1%241 up, 0 downApr 26, 2022$1.34B
    Dec 31, 2021$0.51$0.55$0.53 - $0.57-7.27%Miss+2.0%220 up, 0 downJan 26, 2022$1.33B
    Sep 30, 2021$0.54$0.53$0.51 - $0.56+1.89%Beat+5.9%230 up, 1 downOct 27, 2021$1.31B
    Jun 30, 2021$0.64$0.55$0.50 - $0.64+16.36%Beat+88.2%24N/AJul 29, 2021$1.38B
    Mar 31, 2021$0.54$0.47$0.43 - $0.50+14.89%Beat+8.0%23N/AApr 20, 2021$1.22B
    Dec 31, 2020$0.50$0.53$0.48 - $0.57-5.66%Miss+2.0%22N/AJan 27, 2021$1.19B
    Sep 30, 2020$0.51$0.44$0.40 - $0.48+15.91%Beat+8.5%22N/AOct 21, 2020$1.14B
    Jun 30, 2020$0.34$0.19-$0.19 - $0.27+78.95%Beat-26.1%21N/AJul 23, 2020$925.00M
    Mar 31, 2020$0.50$0.41$0.30 - $0.53+21.95%Beat+13.6%20N/AApr 23, 2020$1.13B
    Dec 31, 2019$0.49$0.50$0.48 - $0.52-2.00%Miss+25.6%20N/AJan 30, 2020$1.17B
    Sep 30, 2019$0.47$0.41$0.40 - $0.42+14.63%Beat+30.6%21N/AOct 23, 2019$1.09B
    Jun 30, 2019$0.46$0.44$0.43 - $0.46+4.55%Beat+12.2%22N/AJul 23, 2019$1.09B
    Mar 31, 2019$0.44$0.41$0.39 - $0.44+7.32%Beat+7.3%22N/AApr 23, 2019$993.00M
    Dec 31, 2018$0.39$0.39$0.38 - $0.410.00%In line+25.8%24N/AJan 31, 2019$977.70M
    Sep 30, 2018$0.36$0.34$0.32 - $0.35+5.88%Beat+28.6%21N/AOct 23, 2018$906.60M
    Jun 30, 2018$0.41$0.38$0.37 - $0.40+7.89%Beat+13.9%20N/AJul 26, 2018$943.70M
    Mar 31, 2018$0.41$0.37$0.36 - $0.39+10.81%Beat+32.3%20N/AApr 24, 2018$894.80M
    Dec 31, 2017$0.31$0.30$0.29 - $0.32+3.33%Beat+24.0%20N/AFeb 1, 2018$888.50M
    Sep 30, 2017$0.28$0.29$0.27 - $0.31-3.45%Miss+21.7%21N/AOct 24, 2017$821.50M
    Jun 30, 2017$0.36$0.29$0.29 - $0.31+24.14%Beat+44.0%21N/AJul 26, 2017$841.80M
    Mar 31, 2017$0.31$0.27N/A+14.81%Beat+29.2%N/AN/AApr 25, 2017$883.50M
    Dec 31, 2016$0.25$0.24N/A+4.17%Beat+19.0%N/AN/AFeb 1, 2017$767.70M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $2.56, down 2.3% from the year before. It was $0.97 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$2.56-2.3%
    Dec 31, 2024$2.62+4.4%
    Dec 31, 2023$2.51N/A
    Dec 31, 2022$2.48+11.2%
    Dec 31, 2021$2.23+20.5%
    Dec 31, 2020$1.85N/A
    Dec 31, 2019$1.86+18.5%
    Dec 31, 2018$1.57+24.6%
    Dec 31, 2017$1.26+29.9%
    Dec 31, 2016$0.97N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,300 words across 12 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,31312
    2026Q2Jun 30, 20266,85213
    2025Q4Dec 31, 20257,96313
    2025Q3Sep 30, 20257,61812
    2025Q2Jun 30, 20258,33917
    2025Q1Mar 31, 20258,88715
    2024Q4Dec 31, 20245,64011
    2024Q3Sep 30, 20246,27617

    2026Q3 Earnings Call

    Opening remarks

    Gerianne Sarte Senior Vice President, Investor Relations Good afternoon, and thank you for joining us. With me on today's call is our CEO, Bernard Zovighian, and our CFO, Doretta Mistras. Also joining us for the Q&A portion of the call will be Dan Lippis, our Global Leader of TAVR, and Daveen Chopra, who has global responsibility for TMTT, Surgical, and IHFM. After the close of regular trading, Edwards Lifesciences released third quarter 2026 financial results. During today's call, management will discuss the results included in the press release and accompanying financial schedules and then use the remaining time for Q&A. Please note that management will be making forward-looking statements that are based on estimates, assumptions, and projections. These statements speak only as of the date on which they are made, and Edwards does not undertake any obligation to update them after today. Additionally, the statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. Factors that could cause these differences can be found in today's press release and Edwards' other SEC filings, all of which are available on the company's website at edwards.com. Unless otherwise noted, our commentary on sales growth refers to underlying sales growth, which is defined in the financial results press release issued earlier today. Reconciliations between GAAP and non-GAAP numbers mentioned during this call are also included in today's press release. Quarterly and full-year growth rates refer to continuing operations. With that, I'll turn the call over to Bernard for his comments.

    Bernard Zovighian CEO Thank you, Gerianne, and welcome, everyone. We delivered third-quarter results that exceeded expectations, with both our businesses and regions driving strong, broad-based performance. Even more importantly, we achieved meaningful progress on several of our most important clinical, regulatory policy, and commercial priorities, strengthening our outlook for durable long-term growth. The consistency of our top-tier financial performance is a reflection of our focused strategy, as well as our commitment to innovation, speed and agility, and the strength of execution by our 17,000 dedicated employees across Edwards. Third-quarter sales of $1.72 billion grew 11.2%. This performance was driven by our structural heart portfolio, including continued strength in TAVR and growing contributions from our portfolio of TMTT therapies with PASCAL, EVOQUE, and SAPIEN M3. Based on our strong performance this quarter, we are raising our full-year sales growth guidance to approximately 11.5% and our adjusted EPS guidance to $2.97 to $3.05, growing 18% at the midpoint versus the prior year. As I reflect on 2026 so far, I am proud of what our teams have accomplished and how we are positioning Edwards for the future.

    Frequently Asked Questions About EW

    When is Edwards Lifesciences's next earnings date?

    Edwards Lifesciences's next earnings report is expected for Feb 8, 2027.

    Did EW beat earnings estimates last quarter?

    Yes. Edwards Lifesciences reported EPS of $0.80 for the quarter ended Sep 30, 2026, above the $0.73 estimate, a 9.59% surprise.

    What EPS do analysts expect from EW next quarter?

    The consensus EPS estimate for Edwards Lifesciences for the quarter ending Dec 31, 2026 is $0.69 from 28 analysts, with estimates from $0.63 to $0.79.

    How often does EW beat earnings estimates?

    Edwards Lifesciences beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +6.45%.